Department of Small Animal Clinical Sciences, Small Animal Hospital, School of Veterinary Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Department of Small Animal Clinical Sciences, University of Tennessee, Knoxville, Tennessee, USA.
J Vet Intern Med. 2020 May;34(3):1078-1090. doi: 10.1111/jvim.15757. Epub 2020 May 12.
Currently, the pathogenesis of congestive heart failure (CHF) in cats is not fully understood.
To identify novel biomarkers for CHF in cats caused by primary cardiomyopathy, particularly related to cardiovascular-renal axis disorder and systemic inflammatory response.
Twenty-five cats in CHF caused by primary cardiomyopathy, 12 cats with preclinical cardiomyopathy, and 20 healthy controls.
Case control and observational case series. The following serum biomarkers were compared among the 3 cat groups: a cardiorenal profile that included N-terminal pro-brain natriuretic peptide (NT-proBNP), symmetric dimethylarginine (SDMA), and creatinine and an inflammatory profile that included 7 acute-phase proteins (APPs). Survival analyses and longitudinal studies were performed in CHF cats.
All cardiorenal biomarkers were positively correlated and higher in CHF cats, and high NT-proBNP and SDMA were associated with poor clinical outcome. Cats with CHF had significantly higher leucine-rich alpha-2-glycoprotein 1, serum amyloid A, and ceruloplasmin, and these APPs were positively correlated with NT-proBNP and left atrial size. In a multivariable survival analysis, alpha-1-acid glycoprotein concentration (P = .01), body weight (P = .02) and left atrial-to-aortic root ratio (P = .01) were independent prognostic factors for CHF in these cats.
In cats, CHF is an inflammatory disorder and outcome in CHF may be determined by the extent of inflammation and possibly the amount of residual renal function. These novel biomarkers have potential use for the clinical management, prognosis, and future research into CHF and cardiomyopathy in cats.
目前，猫充血性心力衰竭（CHF）的发病机制尚不完全清楚。
确定原发性心肌病引起的猫 CHF 的新型生物标志物，特别是与心血管-肾脏轴紊乱和全身炎症反应相关的生物标志物。
25 只患有原发性心肌病的 CHF 猫，12 只处于临床前心肌病的猫和 20 只健康对照猫。
病例对照和观察性病例系列研究。比较了 3 组猫的以下血清生物标志物：包括 N 末端脑利钠肽前体（NT-proBNP）、对称二甲基精氨酸（SDMA）和肌酐的心脏肾脏生物标志物谱，以及包括 7 种急性时相蛋白（APPs）的炎症生物标志物谱。对 CHF 猫进行了生存分析和纵向研究。
所有心脏肾脏生物标志物均呈正相关，且 CHF 猫的标志物水平较高，高 NT-proBNP 和 SDMA 与不良临床结局相关。患有 CHF 的猫的白细胞丰富的α-2-糖蛋白 1、血清淀粉样 A 和铜蓝蛋白显著升高，这些 APPs 与 NT-proBNP 和左心房大小呈正相关。在多变量生存分析中，α-1-酸性糖蛋白浓度（P =.01）、体重（P =.02）和左心房-主动脉根比（P =.01）是这些猫 CHF 的独立预后因素。
在猫中，CHF 是一种炎症性疾病，CHF 的结局可能取决于炎症的程度，以及可能的残余肾功能。这些新型生物标志物具有用于 CHF 和猫心肌病的临床管理、预后和未来研究的潜力。
